Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Gild crawled time : 01:00 save search
Everest Medicines Announces Interim Results for First Half of 2023
Published: 2023-08-24 (Crawled : 01:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.5%
H: 0.45%
C: -0.86%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.27%
H: 1.15%
C: -1.19%
CALT | $17.65 -2.4% 4K
|
Health Technology
|
| O: -4.72%
H: 0.0%
C: 0.0%
results
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
Published: 2023-03-27 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.48%
H: 0.76%
C: -1.0%
payment
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.1%
H: 0.15%
C: -0.35%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -2.12%
H: 2.19%
C: 1.5%
extension study ulcerative colitis
Gilead Sciences to Present at Upcoming Investor Conferences - November 15, 2022
Published: 2022-11-15 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.34%
H: 0.61%
C: -0.16%
sciences
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
Published: 2022-08-15 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.41%
H: 3.83%
C: 3.7%
trodelvy acquire
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
Published: 2022-05-24 (Crawled : 01:00) - biospace.com/
KODK | $4.62 0.22% 0.65% 540K
|
Electronic Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 0.17%
H: 5.38%
C: -0.17%
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-30 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.18%
H: 0.53%
C: -1.26%
drug application cancer breast cancer
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-31 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.52%
H: 0.08%
C: -0.87%
drug application cancer breast cancer
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.95%
H: 0.0%
C: 0.0%
financial results technology report results biotech iot
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-02-07 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.42%
H: 0.0%
C: 0.0%
trodelvy drug approval cancer negative breast cancer
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
jyseleca treatment license ulcerative colitis
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
new drug fda application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-14 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
new drug application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-15 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.99%
H: 1.23%
C: 0.94%
new drug application drug cancer negative breast cancer
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-05-06 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.71%
H: 0.97%
C: 0.76%
food cancer drug breast cancer designation
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Published: 2021-04-09 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.31%
H: 0.66%
C: 0.45%
treatment fda fda approval cancer breast cancer approval license
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.